MX2023011669A - Uso de un agonista del receptor de orexina 2 para la recuperacion posoperatoria. - Google Patents
Uso de un agonista del receptor de orexina 2 para la recuperacion posoperatoria.Info
- Publication number
- MX2023011669A MX2023011669A MX2023011669A MX2023011669A MX2023011669A MX 2023011669 A MX2023011669 A MX 2023011669A MX 2023011669 A MX2023011669 A MX 2023011669A MX 2023011669 A MX2023011669 A MX 2023011669A MX 2023011669 A MX2023011669 A MX 2023011669A
- Authority
- MX
- Mexico
- Prior art keywords
- orexin
- post operation
- receptor agonist
- operation recovery
- methyl
- Prior art date
Links
- RHLMXWCISNJNDH-UHFFFAOYSA-N n-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide Chemical compound COC1=CC=C(C=2C=C(C=CC=2)C(=O)N(C)C)C=C1S(=O)(=O)NC(C=1)=CC=CC=1NCCNC(=O)C1=CC=CC(C)=C1 RHLMXWCISNJNDH-UHFFFAOYSA-N 0.000 title 1
- 238000011084 recovery Methods 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- -1 (4-phenylcyclohexyl)oxy Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170211P | 2021-04-02 | 2021-04-02 | |
| PCT/IB2022/053085 WO2022208478A1 (en) | 2021-04-02 | 2022-04-01 | Use of an orexin 2 receptor agonist for post operation recovery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011669A true MX2023011669A (es) | 2023-10-18 |
Family
ID=81326367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011669A MX2023011669A (es) | 2021-04-02 | 2022-04-01 | Uso de un agonista del receptor de orexina 2 para la recuperacion posoperatoria. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240165092A1 (https=) |
| EP (1) | EP4313045A1 (https=) |
| JP (1) | JP2024511676A (https=) |
| KR (1) | KR20230165782A (https=) |
| CN (1) | CN117396203A (https=) |
| AU (1) | AU2022252108A1 (https=) |
| BR (1) | BR112023020104A2 (https=) |
| CA (1) | CA3215906A1 (https=) |
| CO (1) | CO2023013001A2 (https=) |
| MX (1) | MX2023011669A (https=) |
| TW (1) | TW202304437A (https=) |
| WO (1) | WO2022208478A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202502342A (zh) * | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| CA3154321A1 (en) * | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2022
- 2022-04-01 BR BR112023020104A patent/BR112023020104A2/pt unknown
- 2022-04-01 CN CN202280037124.XA patent/CN117396203A/zh active Pending
- 2022-04-01 US US18/553,348 patent/US20240165092A1/en active Pending
- 2022-04-01 CA CA3215906A patent/CA3215906A1/en active Pending
- 2022-04-01 TW TW111112864A patent/TW202304437A/zh unknown
- 2022-04-01 AU AU2022252108A patent/AU2022252108A1/en active Pending
- 2022-04-01 WO PCT/IB2022/053085 patent/WO2022208478A1/en not_active Ceased
- 2022-04-01 EP EP22715747.6A patent/EP4313045A1/en active Pending
- 2022-04-01 KR KR1020237033928A patent/KR20230165782A/ko active Pending
- 2022-04-01 MX MX2023011669A patent/MX2023011669A/es unknown
- 2022-04-01 JP JP2023560767A patent/JP2024511676A/ja active Pending
-
2023
- 2023-09-29 CO CONC2023/0013001A patent/CO2023013001A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022208478A1 (en) | 2022-10-06 |
| KR20230165782A (ko) | 2023-12-05 |
| CO2023013001A2 (es) | 2023-10-30 |
| CN117396203A (zh) | 2024-01-12 |
| US20240165092A1 (en) | 2024-05-23 |
| CA3215906A1 (en) | 2022-10-06 |
| JP2024511676A (ja) | 2024-03-14 |
| AU2022252108A1 (en) | 2023-10-05 |
| BR112023020104A2 (pt) | 2023-11-14 |
| TW202304437A (zh) | 2023-02-01 |
| EP4313045A1 (en) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69934435D1 (de) | Methoden zum befeuchten der nasenschleimhaut | |
| BRPI0408784A (pt) | método para usar um composto | |
| MX2023011669A (es) | Uso de un agonista del receptor de orexina 2 para la recuperacion posoperatoria. | |
| ES2531190T3 (es) | Método para producir un compuesto de 4-oxoquinolina | |
| CY1110800T1 (el) | Μεθανοσουλφονικα αλατα αβιρατερονης-3-εστερων και ανακτηση αλατων αβιρατερονης-3-εστερων απο διαλυμα σε μεθυλο τριτ-βουτυλαιθερα | |
| MX2022003017A (es) | Uso de un agonista del receptor de orexina 2 para tratamiento de somnolencia excesiva. | |
| JOP20250110A1 (ar) | ناهضات مستقبل الببتيد الشبيه بالجلوكاجون-1 | |
| MX2009004900A (es) | Arilamidas sustituidas por tiazol u oxazol. | |
| BR0212652A (pt) | Composição para o tratamento de uma formação subterrânea, método de tratamento de uma formação subterrânea para aumentar a permeabilidade, e método de tratamento de um conjunto de escoramento numa fratura numa formação subterrânea para aumentar a sua permeabilidade | |
| TW200833682A (en) | Pharmaceutical compounds | |
| MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| DK1501808T3 (da) | Tachykininreceptor-antagonister | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| NO20051970L (no) | Fremgangsmate for fremstilling av valsartan og mellomprodukter for fremgangsmaten samt fremstilling derav. | |
| DK1694318T3 (da) | (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum | |
| WO2007088276A3 (fr) | Derives de sulfonamides, leur preparation et leur application en therapeutique | |
| ATE309249T1 (de) | Chemokin rezeptor antagonisten und verwndung | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA201171305A1 (ru) | Терапевтическое средство при моторных нарушениях | |
| JP2020512356A5 (https=) | ||
| PH12021552902A1 (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor | |
| WO2020236690A9 (en) | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | |
| MX2009012331A (es) | Compuesto carbamoiloxiarilalcanoilarilpiperazina novedoso, composiciones farmaceuticas que comprenden el compuesto y metodo para el tratamiento de dolor, ansiedad y depresion mediante la administracion del compuesto. | |
| HRP20050075B1 (hr) | Primjena specifiäśnog derivata cikliäśkog amina ili njegovih farmaceutski prihvatljivih soli u lijeäśenju ili prevenciji zatajenja srca | |
| DK1511466T3 (da) | Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD |